About NuProbe
NuProbe is a company based in George Town (Cayman Islands) founded in 2016 by Junfeng Luo, Yundi Chen, Yingshuang Chai, Victor Shi, Peng Yin, and David Yu Zhang. NuProbe has raised $61 million across 4 funding rounds from investors including Astrazeneca, CICC and WuXi AppTec. NuProbe offers products and services including BDA Technology, QASeq, and Custom Assay Development. NuProbe operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter George Town, Cayman Islands
- Founders Junfeng Luo, Yundi Chen, Yingshuang Chai, Victor Shi, Peng Yin, David Yu Zhang
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$61 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jan 11, 2021
-
Investors
Astrazeneca
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NuProbe
NuProbe offers a comprehensive portfolio of products and services, including BDA Technology, QASeq, and Custom Assay Development.
Enables selective PCR amplification of low-abundant DNA variants.
Detects mutations and copy variations using multiplexed PCR.
Provides tailored assays for biomarker detection in research.
People of NuProbe
Unlock access to complete
Unlock access to complete
Funding Insights of NuProbe
NuProbe has successfully raised a total of $61M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NuProbe
NuProbe has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, CICC and WuXi AppTec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for NuProbe
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NuProbe
Investment portfolio details for NuProbe
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NuProbe
Detailed financials for NuProbe
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nuprobe Comparisons
Peer comparison for NuProbe
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NuProbe
NuProbe operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of NuProbe
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nuprobe
Complete news archive for NuProbe
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NuProbe
NuProbe was founded in 2016 and raised its 1st funding round 2 years after it was founded.
NuProbe is headquartered in George Town, Cayman Islands.
NuProbe is a funded company, having raised a total of $61M across 4 funding rounds to date.
NuProbe was founded in 2016 in George Town, Cayman Islands, within the biotechnology sector. A multiplexed platform for quantitative PCR is provided, featuring toehold probe designs that enable discrimination of single nucleotide variants through thermodynamics-guided methods. Applications are targeted at rare allele detection in cancer diagnostics, noninvasive prenatal testing, infectious disease screening, and related fields. Operations focus on tool development for these diagnostic areas.
NuProbe's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
NuProbe offers BDA Technology, QASeq, and Custom Assay Development.
NuProbe has 14 investors. Key investors include Astrazeneca, CICC, WuXi AppTec, HHS, and BioTrack Capital.